You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 12, 2025

Drug Sales Trends for MOBIC


✉ Email this page to a colleague

« Back to Dashboard


Drug Sales Revenue Trends for MOBIC
Drug Units Sold Trends for MOBIC

Annual Sales Revenues and Units Sold for MOBIC

These sales figures are drawn from a US national survey of drug expenditures

Meloxicam (MOBIC) Market Analysis and Sales Projections

Last updated: January 2, 2025

Introduction to Meloxicam (MOBIC)

Meloxicam, commonly known by its brand name MOBIC, is a non-steroidal anti-inflammatory drug (NSAID) widely used for the treatment of pain and inflammation associated with various musculoskeletal disorders, including osteoarthritis, rheumatoid arthritis, and other chronic pain conditions. Here’s a comprehensive analysis of the market trends, growth drivers, and sales projections for meloxicam.

Market Size and Growth Projections

The global meloxicam market is anticipated to experience significant growth over the coming years. As of 2023, the market size was valued at over USD 7 billion and is projected to reach USD 47 billion by 2036, growing at a Compound Annual Growth Rate (CAGR) of around 5% during the forecast period of 2024-2036[1].

Another report indicates that the meloxicam market was valued at USD 2.8 billion in 2023 and is expected to grow to USD 4.2 billion by 2031, with a CAGR of 4.5% from 2024 to 2031[4].

Growth Drivers

Rising Prevalence of Chronic Pain and Arthritis

The increasing prevalence of chronic pain and arthritis, particularly among the aging population, is a major driver of the meloxicam market. Conditions such as osteoarthritis and rheumatoid arthritis are becoming more common, leading to a higher demand for effective pain relief medications. According to the World Health Organization, 60% of those with osteoarthritis are female, and 73% are older than 55[1].

Shift Toward Safer Pain Management Options

There is a growing shift towards safer pain management options due to concerns over the side effects of certain pain relief medications, such as opioids. Meloxicam, with its reduced gastrointestinal side effects compared to other NSAIDs, is becoming a preferred choice for long-term use in chronic conditions[2].

Development of Novel Formulations

The availability of cost-effective generic versions and innovative formulations of meloxicam is making it more accessible and affordable for patients. This increased accessibility, combined with the rising awareness of the benefits of meloxicam, is driving market growth[2].

Market Segmentation

By Application

The meloxicam market is segmented based on application, including tablets, capsules, oral suspension, and injectable solutions. Each form has its own market share and growth prospects, with tablets and capsules being the most common forms due to their ease of administration and patient compliance[4].

By Product

The market is also segmented by product, including pain relief, anti-inflammatory treatment, osteoarthritis management, and rheumatoid arthritis treatment. The osteoarthritis segment is expected to account for the largest revenue share, driven by the rising prevalence and consumer awareness of treatment options[1].

By Geography

Geographically, the meloxicam market is divided into regions such as North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.

  • North America: This region is anticipated to account for the largest revenue share, driven by the increasing number of arthritis and other chronic pain disease patients, along with escalating healthcare infrastructure and research and development activities[1].
  • Asia-Pacific: The APAC region is expected to see significant growth due to the growing aging population and increasing incidence of osteoarthritis, rheumatoid arthritis, and other inflammatory conditions. Favorable reimbursement policies for generic drugs are also driving market growth in this region[1].

Challenges and Opportunities

Challenges

Despite the growth prospects, the meloxicam market faces challenges such as the potential side effects associated with long-term use, including cardiovascular risks and gastrointestinal issues. Additionally, the presence of other pain management options and the regulatory environment can impact market dynamics[1].

Opportunities

The increasing demand for safer pain management options and the development of novel formulations present significant opportunities for the meloxicam market. The growing healthcare infrastructure and ongoing research into new therapeutic uses of meloxicam are also expected to drive market expansion[2][4].

Key Statistics and Trends

  • Prevalence of Arthritis: According to the CDC, 53.2 million US individuals, or 1 in 4, have some form of arthritis, with osteoarthritis affecting 32.5 million US adults[1].
  • Market Share: The osteoarthritis segment is estimated to account for the largest revenue share of 40% by the end of 2036[1].
  • Generic Formulations: The availability of generic equivalents is improving accessibility and affordability, driving market growth[4].

Quotes from Industry Experts

"Meloxicam has become a preferred choice for both patients and healthcare professionals due to its long-lasting pain relief and reduced gastrointestinal side effects compared to other NSAIDs," said a healthcare expert, highlighting the drug's efficacy and safety profile[2].

Illustrative Statistics

  • Market Size: Expected to reach USD 47 billion by 2036[1].
  • CAGR: Growing at a CAGR of around 5% from 2024 to 2036[1].
  • Prevalence: 60% of those with osteoarthritis are female, and 73% are older than 55[1].

Highlight

"Meloxicam is an effective pain management medication highly used in the treatment of osteoarthritis, juvenile rheumatoid arthritis, and rheumatoid arthritis, especially among the old population," - Research Nester[1].

Key Takeaways

  • The global meloxicam market is expected to grow significantly, driven by the increasing prevalence of chronic pain and arthritis.
  • The shift towards safer pain management options and the development of novel formulations are key growth drivers.
  • The market is segmented by application, product, and geography, with North America and the Asia-Pacific region showing significant growth potential.
  • Despite challenges, the market presents opportunities for growth due to increasing demand for safer pain management and ongoing research.

FAQs

  1. What is the projected market size of meloxicam by 2036? The meloxicam market is anticipated to reach USD 47 billion by the end of 2036[1].

  2. What are the primary drivers of the meloxicam market growth? The primary drivers include the rising prevalence of chronic pain and arthritis, a shift towards safer pain management options, and the development of novel formulations[1][2].

  3. Which region is expected to account for the largest revenue share in the meloxicam market? North America is anticipated to account for the largest revenue share by the end of the forecast period[1].

  4. What are the common forms of meloxicam available in the market? Meloxicam is available in forms such as tablets, capsules, oral suspension, and injectable solutions[4].

  5. Why is meloxicam preferred over other NSAIDs? Meloxicam is preferred due to its long-lasting pain relief and reduced gastrointestinal side effects compared to other NSAIDs[2].

Sources

  1. Research Nester, "Meloxicam Market Size - Global Forecast Report 2036"[1].
  2. Market Research Intellect, "Meloxicam Drug Sales: Insights into Growth Trends and Market Evolution"[2].
  3. Business Wire, "Meloxicam Sales, Price Analysis, & Sales Forecasts 2016-2021 --- Research and Markets"[3].
  4. Market Research Intellect, "Meloxicam Drug Market Size, Share | Industry Research Report 2031"[4].
  5. News Channel Nebraska, "Meloxicam Drug Market Growth 2024: Key Drivers and Innovative Technologies Forecast to 2031"[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.